Background Patients with advanced-stage non–small cell lung cancer with epidermal
growth factor receptor (EGFR) mutations are successfully treated with tyrosine kinase …

7074 Background: Gefitinib is effective as a 2nd or 3rd line treatment for non-small cell lung
cancer (NSCLC), but efficacy for chemotherapy-naïve patients (pts) with NSCLC has not …

Background. Gefitinib resistance remains a major problem in the treatment of lung cancer.
However, the underlying mechanisms involved in gefitinib resistance are largely unclear …

There is no consensus on the optimal treatment for patients with advanced non-small-cell
lung cancer (NSCLC) and stable disease (SD) after gefitinib therapy. This randomized, open …

Objective The primary purpose of this study was to investigate the correlation between
single nucleotide polymorphisms (SNPs) of ATP binding cassette superfamily G member 2 …

The epidermal growth factor receptor (EGFR) is expressed in the majority of non-small-cell
lung cancer (NSCLC). However, only a restricted subgroup of NSCLC patients respond to …

Objective: The aim of the study was to explore the association of pharmacokinetic variability
and pharmacogenomics with the bioequivalence of orally administered gefitinib (Iressa® …

Patients with epidermal growth factor receptor (EGFR) wild-type non-small cell lung cancer
(NSCLC) often show primary resistance to gefitinib therapy. It is thus necessary to study the …

Background Gefitinib is a tyrosine kinase inhibitor (TKI) of the epidermal growth factor
receptor (EGFR) especially effective in tumors with activating EGFR gene mutations while …

Background Gefitinib is recommended as a first-line treatment option for elderly patients with
non-small cell lung cancer (NSCLC). Because no pharmacokinetics of gefitinib have been …